Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours
- Funding to support development of first-in-class CLDN1 targeted medicines
- Strong syndicate of international life science investors
- One of the largest ADC-focused private fundraisings globally in 2024
Copenhagen, Denmark, 12 November 2024 – Novo Holdings, a leading global life science investor, today announced that it has co-led a $181.4 million Series D financing in Alentis Therapeutics (“Alentis”). Alentis is a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.
